{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:47:36Z","timestamp":1759063656319},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.vaccine.2011.12.103","type":"journal-article","created":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:23:52Z","timestamp":1325809432000},"page":"1465-1475","source":"Crossref","is-referenced-by-count":12,"title":["Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling"],"prefix":"10.1016","volume":"30","author":[{"given":"Evandro R.","family":"Winkelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas G.","family":"Widman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingya","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindy","family":"Miller-Kittrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle H.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Scholle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg N.","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"April (17)","key":"10.1016\/j.vaccine.2011.12.103_bib0005","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"March\u2013April (2)","key":"10.1016\/j.vaccine.2011.12.103_bib0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccin"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2011.12.103_bib0015","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1128\/CVI.00119-09","article-title":"Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys","volume":"16","author":"Lieberman","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2011.12.103_bib0020","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1086\/523650","article-title":"A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial","volume":"196","author":"Martin","year":"2007","journal-title":"J Infect Dis"},{"issue":"May (22)","key":"10.1016\/j.vaccine.2011.12.103_bib0025","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1016\/j.vaccine.2008.03.009","article-title":"Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system","volume":"26","author":"Widman","year":"2008","journal-title":"Vaccine"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2011.12.103_bib0030","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.virol.2006.04.003","article-title":"Production and characterization of vaccines based on flaviviruses defective in replication","volume":"351","author":"Mason","year":"2006","journal-title":"Virology"},{"issue":"September (41)","key":"10.1016\/j.vaccine.2011.12.103_bib0035","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1016\/j.vaccine.2009.07.016","article-title":"RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters","volume":"27","author":"Widman","year":"2009","journal-title":"Vaccine"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2011.12.103_bib0040","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.4269\/ajtmh.2010.09-0310","article-title":"Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection","volume":"82","author":"Widman","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2011.12.103_bib0045","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0952-7915(02)00354-0","article-title":"Links between innate and adaptive immunity via type I interferon","volume":"14","author":"Le Bon","year":"2002","journal-title":"Curr Opin Immunol"},{"issue":"January (Pt 1)","key":"10.1016\/j.vaccine.2011.12.103_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.83391-0","article-title":"Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures","volume":"89","author":"Randall","year":"2008","journal-title":"J Gen Virol"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2011.12.103_bib0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","article-title":"Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo","volume":"14","author":"Le Bon","year":"2001","journal-title":"Immunity"},{"issue":"December (27 Suppl. 6)","key":"10.1016\/j.vaccine.2011.12.103_bib0060","doi-asserted-by":"crossref","first-page":"G17","DOI":"10.1016\/j.vaccine.2009.10.016","article-title":"Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity","author":"Prchal","year":"2009","journal-title":"Vaccine"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2011.12.103_bib0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4049\/jimmunol.169.1.375","article-title":"Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model","volume":"169","author":"Proietti","year":"2002","journal-title":"J Immunol"},{"issue":"March (1)","key":"10.1016\/j.vaccine.2011.12.103_bib0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virol.2008.11.034","article-title":"West Nile virus genome amplification requires the functional activities of the proteasome","volume":"385","author":"Gilfoy","year":"2009","journal-title":"Virology"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2011.12.103_bib0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.virol.2004.10.046","article-title":"Adaptation of West Nile virus replicons to cells in culture and use of replicon-bearing cells to probe antiviral action","volume":"331","author":"Rossi","year":"2005","journal-title":"Virology"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2011.12.103_bib0080","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.4049\/jimmunol.174.11.7217","article-title":"A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection","volume":"174","author":"Banks","year":"2005","journal-title":"J Immunol"},{"issue":"September (17)","key":"10.1016\/j.vaccine.2011.12.103_bib0085","doi-asserted-by":"crossref","first-page":"9100","DOI":"10.1128\/JVI.00316-07","article-title":"Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production","volume":"81","author":"Bourne","year":"2007","journal-title":"J Virol"},{"issue":"December (2)","key":"10.1016\/j.vaccine.2011.12.103_bib0235","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.vaccine.2010.10.069","article-title":"Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine","volume":"29","author":"Nelson","year":"2010","journal-title":"Vaccine"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2011.12.103_bib0100","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/eji.200737192","article-title":"Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis","volume":"37","author":"Purtha","year":"2007","journal-title":"Eur J Immunol"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2011.12.103_bib0105","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/eji.200737196","article-title":"Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection","volume":"37","author":"Brien","year":"2007","journal-title":"Eur J Immunol"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2011.12.103_bib0110","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.4049\/jimmunol.181.12.8568","article-title":"West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection","volume":"181","author":"Brien","year":"2008","journal-title":"J Immunol"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2011.12.103_bib0115","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4049\/jimmunol.0900460","article-title":"MyD88 and Type I interferon receptor-mediated chemokine induction and monocyte recruitment during Listeria monocytogenes infection","volume":"183","author":"Jia","year":"2009","journal-title":"J Immunol"},{"issue":"January (1\u20133)","key":"10.1016\/j.vaccine.2011.12.103_bib0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0014-5793(01)03276-8","article-title":"A non-classical ISRE\/ISGF3 pathway mediates induction of RANTES gene transcription by type I IFNs","volume":"511","author":"Cremer","year":"2002","journal-title":"FEBS Lett"},{"issue":"May (9)","key":"10.1016\/j.vaccine.2011.12.103_bib0125","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1128\/JVI.76.9.4520-4525.2002","article-title":"Promotion of alpha\/beta interferon induction during in vivo viral infection through alpha\/beta interferon receptor\/STAT1 system-dependent and -independent pathways","volume":"76","author":"Malmgaard","year":"2002","journal-title":"J Virol"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2011.12.103_bib0240","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","article-title":"Type I interferon inhibits interleukin-1 production and inflammasome activation","volume":"34","author":"Guarda","year":"2011","journal-title":"Immunity"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2011.12.103_bib0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1074-7613(03)00208-5","article-title":"Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6","volume":"19","author":"Jego","year":"2003","journal-title":"Immunity"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2011.12.103_bib0140","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.4049\/jimmunol.176.6.3315","article-title":"Cutting edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection","volume":"176","author":"Havenar-Daughton","year":"2006","journal-title":"J Immunol"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2011.12.103_bib0145","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.4049\/jimmunol.174.8.4465","article-title":"Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation","volume":"174","author":"Curtsinger","year":"2005","journal-title":"J Immunol"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2011.12.103_bib0150","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.4049\/jimmunol.176.7.4343","article-title":"Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection","volume":"176","author":"Coro","year":"2006","journal-title":"J Immunol"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2011.12.103_bib0155","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1128\/JVI.69.3.1895-1902.1995","article-title":"Bone marrow is a major site of long-term antibody production after acute viral infection","volume":"69","author":"Slifka","year":"1995","journal-title":"J Virol"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2011.12.103_bib0160","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20050821","article-title":"Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection","volume":"202","author":"Kolumam","year":"2005","journal-title":"J Exp Med"},{"issue":"August (3)","key":"10.1016\/j.vaccine.2011.12.103_bib0165","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.4049\/jimmunol.177.3.1746","article-title":"Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation","volume":"177","author":"Thompson","year":"2006","journal-title":"J Immunol"},{"issue":"November (21)","key":"10.1016\/j.vaccine.2011.12.103_bib0170","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1128\/JVI.00935-08","article-title":"Toll-like receptor 3 has a protective role against West Nile virus infection","volume":"82","author":"Daffis","year":"2008","journal-title":"J Virol"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2011.12.103_bib0175","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/nm1140","article-title":"Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis","volume":"10","author":"Wang","year":"2004","journal-title":"Nat Med"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2011.12.103_bib0180","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.immuni.2008.11.012","article-title":"Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing","volume":"30","author":"Town","year":"2009","journal-title":"Immunity"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2011.12.103_bib0185","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1128\/JVI.01305-07","article-title":"Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1","volume":"82","author":"Fredericksen","year":"2008","journal-title":"J Virol"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2011.12.103_bib0190","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1084\/jem.189.3.521","article-title":"Type I interferons keep activated T cells alive","volume":"189","author":"Marrack","year":"1999","journal-title":"J Exp Med"},{"issue":"June (23)","key":"10.1016\/j.vaccine.2011.12.103_bib0195","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1016\/j.vaccine.2006.03.066","article-title":"Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)","volume":"24","author":"Sanchez","year":"2006","journal-title":"Vaccine"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2011.12.103_bib0200","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/intimm\/14.4.411","article-title":"IFN-alpha\/beta enhances BCR-dependent B cell responses","volume":"14","author":"Braun","year":"2002","journal-title":"Int Immunol"},{"issue":"November (22)","key":"10.1016\/j.vaccine.2011.12.103_bib0205","doi-asserted-by":"crossref","first-page":"10964","DOI":"10.1128\/JVI.01646-08","article-title":"Early B-cell activation after West Nile virus infection requires alpha\/beta interferon but not antigen receptor signaling","volume":"82","author":"Purtha","year":"2008","journal-title":"J Virol"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2011.12.103_bib0210","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/eji.200635993","article-title":"Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses","volume":"36","author":"Fink","year":"2006","journal-title":"Eur J Immunol"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2011.12.103_bib0215","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.170.2.749","article-title":"Down-modulation of responses to type I IFN upon T cell activation","volume":"170","author":"Dondi","year":"2003","journal-title":"J Immunol"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2011.12.103_bib0220","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.4049\/jimmunol.169.12.6842","article-title":"The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells","volume":"169","author":"Valenzuela","year":"2002","journal-title":"J Immunol"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2011.12.103_bib0225","first-page":"247","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2011.12.103_bib0230","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11020548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11020548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T06:03:26Z","timestamp":1593497006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11020548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0264410X11020548"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.103","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}